Rengangyongsheng (Hong Kong) Limited considers that demand for proprietary Chinese medicines and health supplements in the Hong Kong market is growing steadily, with consumers increasingly seeking high quality and safety assurance. In future, the sector will place greater emphasis on scientific validation, standardised manufacturing and digital compliance management. Cross-border trade will benefit from policy optimisation and greater regulatory transparency. We recommend that businesses embrace innovation, strengthen communication with regulators, and improve product quality and compliance systems to address changing market conditions and regulatory requirements and gain a competitive edge.
HONG KONG DRUG LICENSING
What are Rengangyongsheng (Hong Kong) Limited’s insights into the future development of the proprietary Chinese medicine and health supplement sectors?
A complete explanation of the regulatory basis, Drew Tang’s recommendations and risk alerts. The original material dates from 2025; read it alongside the latest official requirements.
Original guide, 2025 edition: These FAQs are provided for topic-based reference and have not all been individually checked against current rules. Please confirm fees, personnel, renewal, changes and product requirements against the professional in-depth guide for the relevant licence type and the official requirements in force at the time.
Back to Category J: Cross-border Medicines and Industry Practice (Q451-Q500) Search more questions